Health Security is a $12.7 billion market
Medical countermeasures for biological, chemical, radiological and nuclear attacks, as well as vaccines, therapeutics and diagnostics for emerging infectious diseases
Tecovirimat-SIGA is approved by the EU and the UK for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia
We are a public, commercial-stage pharmaceutical company focused on providing solutions for unmet needs in health security.
Click here to learn more about how SIGA is monitoring the monkeypox outbreak.
U.S. providers seeking guidance on obtaining TPOXX please visit CDC.gov
For foreign governments or other inquiries about TPOXX (Tecovirimat-SIGA), please contact us at firstname.lastname@example.org
(Note: TPOXX is approved by the U.S. FDA and Health Canada for the treatment of Smallpox; Tecovirimat-SIGA is approved by the EU and the UK for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia)